AstraZeneca CEO Bolsters Stake Amid Positive Performance Pascal Soriot, CEO of AstraZeneca, acquired nearly 90,000 shares following the vesting of a performance-based award. The company, valued at $241.3 billion, recently announced promising Phase III trial results for gastric cancer treatment, showcasing significant progress in its therapeutic innovations.2